scholarly journals The influence of soybean extract on the expression level of selected drug transporters, transcription factors and cytochrome P450 genes encoding phase I drug-metabolizing enzymes

2014 ◽  
Vol 85 (5) ◽  
Author(s):  
Anna Bogacz ◽  
Joanna Bartkowiak-Wieczrek ◽  
Przemysław Mikołajczak ◽  
Beata Rakowska-Mrozikiewicz ◽  
Edmund Grześkowiak ◽  
...  
2019 ◽  
Vol 20 (18) ◽  
pp. 4562
Author(s):  
Michaela Šadibolová ◽  
Tomáš Zárybnický ◽  
Tomáš Smutný ◽  
Petr Pávek ◽  
Zdeněk Šubrt ◽  
...  

Sesquiterpenes, the main components of plant essential oils, are bioactive compounds with numerous health-beneficial activities. Sesquiterpenes can interact with concomitantly administered drugs due to the modulation of drug-metabolizing enzymes (DMEs). The aim of this study was to evaluate the modulatory effects of six sesquiterpenes (farnesol, cis-nerolidol, trans-nerolidol, α-humulene, β-caryophyllene, and caryophyllene oxide) on the expression of four phase I DMEs (cytochrome P450 3A4 and 2C, carbonyl reductase 1, and aldo-keto reductase 1C) at both the mRNA and protein levels. For this purpose, human precision-cut liver slices (PCLS) prepared from 10 patients and transfected HepG2 cells were used. Western blotting, quantitative real-time PCR and reporter gene assays were employed in the analyses. In the reporter gene assays, all sesquiterpenes significantly induced cytochrome P450 3A4 expression via pregnane X receptor interaction. However in PCLS, their effects on the expression of all the tested DMEs at the mRNA and protein levels were mild or none. High inter-individual variabilities in the basal levels as well as in modulatory efficacy of the tested sesquiterpenes were observed, indicating a high probability of marked differences in the effects of these compounds among the general population. Nevertheless, it seems unlikely that the studied sesquiterpenes would remarkably influence the bioavailability and efficacy of concomitantly administered drugs.


2021 ◽  
Vol 11 (8) ◽  
pp. 783
Author(s):  
Thawinee Jantararoungtong ◽  
Supaporn Wiwattanakul ◽  
Rawiporn Tiyasirichokchai ◽  
Santirhat Prommas ◽  
Rattanaporn Sukprasong ◽  
...  

The response to 6-mercaptopurine (6-MP) can be altered by genetic polymorphisms in genes encoding drug-metabolizing enzymes and drug transporters. The purpose of this study was to investigate the association between genetic polymorphisms of drug-metabolizing enzymes (TPMT 719A > G (*3C), ITPA 94C > A and ITPA 123G > A) and drug transporters (MRP4 912C > A and MRP4 2269G > A) with 6-MP-related myelotoxicity and hepatotoxicity in Thai children with acute lymphoblastic leukemia (ALL). The prescribed dosage of 6-MP and its adverse effects were assessed from medical records during the first 8 weeks and 9–24 weeks of maintenance therapy. Children with the TPMT*1/*3C genotype had a higher risk of leukopenia with an odds ratio (OR) of 4.10 (95% confidence interval (CI) of 1.06–15.94; p = 0.033) compared to wild type (TPMT*1/*1) patients. Heterozygous TPMT*3C was significantly associated with severe neutropenia with an increased risk (OR, 4.17; 95% CI, 1.25–13.90); p = 0.014) during the first 8 weeks. No association was found among ITPA94C > A, ITPA123G > A, MRP4 912C > A, and MRP4 2269G > A with myelotoxicity and hepatotoxicity. The evidence that TPMT heterozygotes confer risks of 6-MP-induced myelotoxicity also supports the convincing need to genotype this pharmacogenetic marker before the initiation of 6-MP therapy.


2019 ◽  
Vol 47 (10) ◽  
pp. 1040-1049 ◽  
Author(s):  
Wilasinee Dunkoksung ◽  
Nontima Vardhanabhuti ◽  
Pongpun Siripong ◽  
Suree Jianmongkol

2012 ◽  
Vol 53 (10) ◽  
pp. 1934-1944 ◽  
Author(s):  
Olav E. Yri ◽  
Per O. Ekstrøm ◽  
Vera Hilden ◽  
Gustav Gaudernack ◽  
Knut Liestøl ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document